These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19503777)

  • 1. Once-yearly zoledronic acid in hip fracture prevention.
    Demontiero O; Duque G
    Clin Interv Aging; 2009; 4():153-64. PubMed ID: 19503777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of zoledronic acid in the prevention and treatment of osteoporosis.
    Räkel A; Boucher A; Ste-Marie LG
    Clin Interv Aging; 2011; 6():89-99. PubMed ID: 21594000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of osteoporosis in the aging male: focus on zoledronic acid.
    Piper PK; Gruntmanis U
    Clin Interv Aging; 2009; 4():289-303. PubMed ID: 19750231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
    Yang L; Sycheva AV; Black DM; Eastell R
    Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid for prevention and treatment of osteoporosis.
    Recknor C
    Expert Opin Pharmacother; 2011 Apr; 12(5):807-15. PubMed ID: 21385149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
    Moriwaki K; Mouri M; Hagino H
    Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
    Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Bucci-Rechtweg C; Su G; Eriksen EF; Magaziner JS
    Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.
    Ito M; Sone T; Shiraki M; Tanaka S; Irie C; Ota Y; Nakamura T
    Bone; 2018 Jan; 106():179-186. PubMed ID: 29033381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
    J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.